|
 
Dr.
Annette Stemhagen
VP Epidemiology & Risk Management
United BioSource Corporation
and
Dr.
Stefan Blesse
Principal Consultant
Granzer Regulatory Consulting and Services
Purchase
a recording of this audio conference
Does your company market its products in Europe, or are you planning
to enter the EU market? Have you taken the requisite steps to
address risk management? Risk management must be an integral part
of global product development and commericalization. In this audio
conference, our speakers will compare and contrast the FDA and
European Medicines Agency approaches to risk management. Dr. Stemhagen
will focus on the US approache, while Dr. Blesse will provide
an overview of EMEA's Guideline on Risk Management Systems for
Medicinal Products for Human Use. We will also explore the epidemiological
methods for post-authorization safety studies, and ways to reduce
risk.
This audio conference will address:
- Understanding
the EU risk management guideline
- When you
need an EU risk management plan
- The process
for compiling a risk management plan
- The differences
between the EU guideline and FDA guidance documents
About the
speaker:
Dr. Annette
Stemhagen is a pharmacoepidemiologist and Vice President of
Epidemiology and Risk Management with United BioSource Corporation.
Her work focuses on strategies to support the commercialization
of medical products, including meeting regulatory requirements
for risk assessment and risk management. In
2004 she was appointed industry representative to the FDA Drug
Safety and Risk Management Advisory Committee. She is a Fellow
and past Vice President of the International Society of Pharmacoepidemiology,
and a former member of the DIA Board of Directors. She holds an
adjunct faculty appointment at the University of Pennsylvania
School of Medicine.
Dr. Stefan
Blesse is a veterinarian and principal consultant with Granzer
Regulatory Consulting & Services, based in Germany. He has spent
15 years working in Regulatory Affairs, and has held various positions
of global responsibility with both large and small pharmaceutical
companies like Hoechst and Bayer. He has extensive experience
with CTD submmission, and has been involved in submissions around
the world, including The US, Europe and Asia-Pacific.
Who should
attend?
- Regulatory
Affairs Directors and VPs
- Directors
and Managers in Risk Management
- Safety
Directors and Managers
- Epidemiologists
- Outcomes
Researchers
This audio
conference is classified as General Interest.
Purchase
Options
|